<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FT932-8044</title>
	</head>
	<body>
		<main>
			<p>930520 FT  20 MAY 93 / International Company News: Speculation over Upjohn succession UPJOHN, the US pharma-ceuticals group, has announced a series of organisational changes which provoked speculation about who would take charge of the company following the recent death of its chairman and chief executive, Mr Theodore Cooper. The company made a number of senior appointments, but did not name a chief executive or chairman. Mr Ley Smith, president and chief operating officer, presided over Upjohn's annual shareholders meeting. Mr Smith was named acting chief executive in April. He will continue in that office until the board appoints a successor to Mr Cooper. Mr Smith said Upjohn would strive to have 1994 earnings at the same level as in 1993, but did not expect real earnings and sales growth before 1995 when 'the first real revenue impact from our new breakthrough products should begin to occur.'</p>
		</main>
</body></html>
            